Xeroderma pigmentosa
Conditions
Interventions
Test group:half face use of DNA enzyme loaded sunscreen
Control group:half face use of normal sunscreen without DNA enzyme
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
5 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with xeroderma pigmentosum through clinical, pathological, non-invasive or molecular diagnosis; 2. Age between 5 and 65 years old, gender not limited; 3. For secondary NMSC and precancerous lesions, the diameter of a single lesion of NMSC and precancerous lesions should be less than 2cm, the depth less than 2mm, and there should be no sentinel lymph nodes or distant metastasis; Before enrollment, completely clinical remission had been achieved through treatment methods such as surgery and photodynamic therapy; 4. Those who have the habit of using sunscreen on a daily basis; 5. Men and women of childbearing age must agree to take effective contraceptive measures from the date of signing the informed consent form until 3 month after the last application of sunscreen at the end of the study. The clinical pregnancy test result of women of childbearing age must be negative within 7 days before the first application of sunscreen. Postmenopausal women must have been amenorrhea for at least 12 months before they are considered infertile. 6. Voluntarily participate in the research and sign the consent form
Exclusion criteria
Exclusion criteria: 1. There are other diseases on the face that researchers believe may affect the evaluation of therapeutic effects, such as solar dermatitis, etc. 2. Those who have taken phototoxic or photosensitive drugs within 8 weeks; 3. People with severe immune dysfunction; 4. People with keloid-prone constitution; 5. Those who are known to have skin photosensitivity, porphyria or are allergic to sunscreen; 6. People with serious internal diseases, psychological and mental disorders, infectious diseases, or pregnant or lactating women; 7. Have received any drug treatment that may affect the examination of skin lesions within the past 30 days; 8. Those who were considered unsuitable for inclusion by other researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of new NMSCS and precancerous lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of recurrent NMSCS and precancerous lesions;Biomarkers of DNA damage;The quality of life of the subjects; | — |
Countries
China
Contacts
Public ContactZhang Guolong
Shanghai Skin Disease Hospital
Outcome results
None listed